The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Could combinatorial CAR-T approaches lead to curative therapy for multiple myeloma?
Joshua Richter, MD, Mount Sinai Medical Center, New York, NY, discusses whether combining CAR T-cell therapies with other therapeutics such as gamma secretase inhibitors or checkpoint inhibitors could lead to the development of a curative CAR-T strategy, which is currently an unmet need for patients with multiple myeloma (MM). This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Secura Bio: Consultancy, Honoraria; Takeda: Consultancy; Oncopeptides: Consultancy, Honoraria; BMS/Celgene: Consultancy, Honoraria, Membership on an entity’s Board of Directors or advisory committees, Speakers Bureau.
